Just like them, we care about your health and well-being
Bibcode:2023NatCo..14.1095F
Bibliography Wall, B., Stephens, F., Constantin-Teodosiu, D., Marmuthu, K., Macdonald, I., Greenhaff, P
AEs leading to trial product discontinuation occurred in 6/90 (7%) participants in the CagriSema 2.4 mg/2.4 mg group, 11/93 (12%) participants in the CagriSema 1 mg/1 mg group, and 1/91 (1%) in the placebo group
This targeted flavonoid profile is particularly beneficial for individuals who experience respiratory congestion, skin sensitivities, and other allergy-like symptoms driven by mast cell overactivity
Kamalanathan T, Rajeswari IT, Sundaram J (2020) Detection and characterization of phenoloxidase from the larval haemolymph of blow fly, Hemipyrellia tagaliana in response to non-self molecules